SEC Form 4 · accession 0001171843-16-013270
Sucampo Pharmaceuticals, Inc. · SCMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew P Smith
Officer — Chief Financial Officer
Period of report
Nov 15, 2016
Accepted (ET)
Nov 16, 2016 · 4:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001365216
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, Class AF1 | Nov 15, 2016 | S | 1,766 | $15.58 | D | 348 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. Shares were sold in multiple transactions at prices ranging from $15.15 to $16.25, inclusive. Upon request the reporting person will provide Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price.